Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20846776 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL10281482 | 0.79 | CA1 (0.43) | CA1KITPPARATDP1 | |
| SCHEMBL28933820 | 0.79 | CA1 (0.46) | CA1KITPPARA | |
| SCHEMBL16508745 | 0.79 | CA1 (0.46) | CA1KITPPARA | |
| SCHEMBL20846775 | 0.75 | — | — | |
| SCHEMBL84444 | 0.74 | POLB (0.41) | — | |
| SCHEMBL16508792 | 0.74 | CA12 (0.45) | CA1 | |
| SCHEMBL5889230 | 0.69 | CA1 (0.47) | CA1PPARATDP1 | |
| SCHEMBL26214261 | 0.68 | CHRM5 (0.44) | KIT | |
| SCHEMBL28869534 | 0.68 | CA1 (0.50) | CA1PPARATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | CA1 2368/4885KIT 2572/4885PPARA 3242/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | CA1 1801/4885KIT 2072/4885PPARA 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.